Key result
SCUBE1 levels did not differ between patients with USAP, NSTEMI, STEMI, non-cardiac chest pain, and healthy controls, indicating it is not diagnostic for these conditions.
Why the study?
Does SCUBE1 measurement distinguish patients with unstable angina pectoris from those with NSTEMI and non-cardiac chest pain?
Observational (n=230)
Does SCUBE1 measurement distinguish patients with unstable angina pectoris from those with NSTEMI and non-cardiac chest pain?
SCUBE1 is not a useful diagnostic biomarker for distinguishing unstable angina pectoris, NSTEMI, and STEMI from non-cardiac chest pain.
Answers are grounded in this paper and cite their sources.
SCUBE1 should not guide ACS diagnosis in chest pain; leaves open the need for validated biomarkers in prospective studies.
Aim: Signal peptide complement C1r/C1s, Uegf, and Bmp1-epidermal growth factor-like domain-containing protein 1 (SCUBE1) has been used in research as a biomarker in acute coronary syndrome (ACS). The aim of this study is to determine if SCUBE1 and routine laboratory parameters are effective in distinguishing the patients presenting with clinical symptoms of unstable angina pectoris (USAP) from the patients who have non-ST-segment elevated myocardial infarction (NSTEMI) and non-cardiac chest pain patients (NCCP).Materials and Methods: The study group consisted of patients having chest pain or those suspected of having an ACS complaint. The study consisted of 5 groups of 185 patients with USAP, NSTEMI, segment elevation myocardial infarction (STEMI), or NCCP, and a control group of 45 healthy patients (CG). The study was conducted according to the American Heart Association (AHA) guidelines.Results: There was no statistical difference between the patient groups and CG in terms of SCUBE1 (p=0.650). The Troponin I value was significantly lower in the USAP group than the STEMI and NSTEMI groups (p<0.001). There was no difference among the sub-groups of USAP in terms of the SCUBE1, GENSINI, and the GRACE scores (p=0.485, 0.932, 0.585, respectively).Conclusion: SCUBE1 was not diagnostic for USAP, NSTEMI, and STEMI. Further studies to understand the value of SCUBE1 in ACS are needed.
No takes yet. Share an insight, caveat, or question.
Özkan et al. (2017) conducted an observational in Acute coronary syndrome / Chest pain (n=230). SCUBE1 biomarker vs. Healthy controls was evaluated on Difference in SCUBE1 levels between patient groups and healthy controls (p=0.650). SCUBE1 levels did not differ between patients with USAP, NSTEMI, STEMI, non-cardiac chest pain, and healthy controls, indicating it is not diagnostic for these conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: